Abstract Search

ea0090oc5.3 | Oral Communications 5: Adrenal and Cardiovascular Endocrinology 1 | ECE2023

Switching patients with Congenital Adrenal Hyperplasia to Modified release hydrocortisone capsules: relative bioavailability and disease control

Ross Richard John M , Rees Aled , P. Merke Deborah , Arlt Wiebke , Brac De La Perriere Aude , Linden Hirschberg Angelica , Juul Anders , D. C. Newell-Price John , Perry Colin Graham , Prete Alessandro , Reisch Nicole , Stikkelbroeck Monica , A. Touraine Philippe , Mallappa Ashwini , Aslam Naila , Coope Helen , Porter John

Background: Modified-release hydrocortisone (MRHC) capsules (Efmody, Diurnal Ltd, Cardiff, UK), have been developed to replicate the cortisol diurnal rhythm and shown to improve CAH disease control1. We have examined relative bioavailability of MRHC and disease control of congenital adrenal hyperplasia (CAH) patients switched from standard therapy to MRHC.Methods: An open label, randomised, 2 period, crossover study comparing the relative bioavailability...

5 shares

Endocrine Abstracts

Switching patients with Congenital Adrenal Hyperplasia to Modified release hydrocortisone capsules: relative bioavailability and disease control

BiosciAbstracts